Back
  1. Home
  3. Detailed Reference
Download
Paper published in a journal (Scientific congresses and symposiums)
2635P Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: Should we treat beyond two years?
Decruyenaere, A.; Gennigens, Christine; Rottey, S. et al.
2025 • In Annals of Oncology, 36, p. 1414-S1415
Editorial reviewed
Permalink
https://hdl.handle.net/2268/337550
DOI
10.1016/j.annonc.2025.08.3249
 

Files (1)Send toDetailsStatisticsBibliographySimilar publications

Files

Full Text
2635 Optimal treatment renal metastatic.pdf
Publisher postprint (271.72 kB)
Download

All documents in ORBi are protected by a user license.

Send to


Details


Disciplines :
Oncology
Author, co-author :
Decruyenaere, A.
Gennigens, Christine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Rottey, S.
Laenen, A.
Seront, E.
Everaert, E.
Debruyne, P.R.
van den Bulck, H.F.M.
Bastin, J.
Verbiest, A.T.L.
Vulsteke, C.
Schatteman, P.
Luyten, D.
Aspeslagh, S.
Martinez Chanza, N.
De Bock, M.C.M.
Meyskens, T.J.
Verheezen, J.
Brouwers, B.
Beuselinck, B.
More authors (10 more) Less
Language :
English
Title :
2635P Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: Should we treat beyond two years?
Publication date :
September 2025
Event name :
ESMO Congress 2025
Event place :
Berlin, Germany
Event date :
17-21 October 2025
Audience :
International
Journal title :
Annals of Oncology
ISSN :
0923-7534
eISSN :
1569-8041
Publisher :
Elsevier
Volume :
36
Pages :
S1414-S1415
Peer review/Selection committee :
Editorial reviewed
Additional URL :
https://api.elsevier.com/content/article/PII:S0923753425041699?httpAccept=text/xml
Available on ORBi :
since 14 November 2025

Statistics

Number of views
14 (1 by ULiège)
Number of downloads
15 (1 by ULiège)
More statistics
OpenCitations
 
0
OpenAlex citations
 
0

Bibliography

Similar publications


Contact ORBi